Rahul Khara
About Rahul Khara
Rahul Khara serves as General Counsel, having previously held roles at Acceleron, including Vice President, Legal and Chief Compliance Officer, where he led legal and compliance functions and supported the launch of Reblozyl.
Rahul Khara's Current Title as General Counsel
Rahul Khara currently holds the position of General Counsel. In this role, he oversees the legal operations, providing strategic legal advice and ensuring compliance with applicable laws and regulations. His extensive background in legal and compliance functions positions him as a key advisor within the organization.
Rahul Khara's Previous Role at Acceleron
Before becoming General Counsel, Rahul Khara served as Vice President, Legal and Chief Compliance Officer at Acceleron. During his tenure, he managed the commercial legal and compliance functions, supporting the company through several key initiatives. His leadership was instrumental in the launch of Reblozyl, Acceleron's first commercial product.
Rahul Khara's Key Contributions to Acceleron
At Acceleron, Rahul Khara built the commercial compliance program, establishing protocols and processes to ensure regulatory adherence. Additionally, he played a vital role in the acquisition of Acceleron by Merck, leveraging his legal expertise to facilitate the successful merger and integration.
Rahul Khara's Work at Law Firms
Rahul Khara has worked at prestigious law firms, including Arnold & Porter LLP and Sidley Austin LLP. His practice focused on assisting biopharma companies with legal issues related to clinical development, new drug launches, business transactions, compliance, and enforcement. His work has helped these companies navigate complex legal landscapes and achieve their business objectives.
Rahul Khara's Educational Background
Rahul Khara is highly educated, holding a Pharm.D. from the Ernest Mario School of Pharmacy at Rutgers University and a J.D. from the University of Michigan Law School. His dual expertise in pharmacy and law provides a unique and valuable perspective to his role in the biopharma industry.